Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
60.73
-2.02 (-3.22%)
At close: Oct 12, 2026, 4:00 PM EDT
60.75
+0.02 (0.03%)
After-hours: Oct 12, 2026, 7:30 PM EDT
Arrowhead Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 14 analysts polled by S&P Global, Arrowhead Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $107.23. The average 1-year stock price forecast is 76.57% higher than the current stock price, while the lowest is $74 (+21.85%) and the highest is $126 (+107.48%).
Price Target: $107.23 (+76.57%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Arrowhead Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 8 | 8 | 9 | 9 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 2 | 2 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 12 | 12 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bank of America Securities | Bank of America Securities | Buy Maintains $100 | Buy | Maintains | $100 | +64.66% | Oct 12, 2026 |
| Goldman Sachs | Goldman Sachs | Hold Initiates $74 | Hold | Initiates | $74 | +21.85% | Sep 24, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $120 | Buy | Maintains | $120 | +97.60% | Sep 21, 2026 |
| Citi | Citi | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Sep 16, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Sep 16, 2026 |
Financial Forecast
Revenue This Year
461.74M
from 829.45M
Decreased by -44.33%
Revenue Next Year
334.32M
from 461.74M
Decreased by -27.60%
EPS This Year
-3.54
from -0.01
EPS Next Year
-4.93
from -3.54
EPS and Forward PE are based on non-GAAP adjusted numbers.